Treatment Action Group
Treatment Action Group (TAG) is an independent, activist research and policy think tank founded in 1992 that fights HIV, tuberculosis, and hepatitis C through scientific research, policy advocacy, and community organizing, serving researchers, clinicians, donors, and affected communities globally.
- Company typePrivate
- Founded1992
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
What Treatment Action Group does
Treatment Action Group (TAG) is an independent, activist, community-based research and policy think tank founded in January 1992 by members of ACT UP. Based in New York City with a remote team of approximately 20 staff, TAG is dedicated to accelerating the fight against HIV, tuberculosis (TB), and hepatitis C virus (HCV) through policy advocacy, scientific research, and community organizing. It serves researchers, clinicians, policymakers, donors, and affected communities in the U.S. and globally.
TAG's core deliverables include the Pipeline Report — an authoritative assessment of HIV, TB, and HCV research and development — the TAGline newsletter, annual TB Research Funding Trends analyses, and clinical trials databases that function as information infrastructure for the field. The organization earns revenue through a nonprofit funding mix: foundation grants (historically including a $4.7M Bill & Melinda Gates Foundation grant in 2007 and ongoing Unitaid support), corporate sponsorships, individual donations, and limited-edition art fundraising. It maintains public accountability through a Platinum Seal of Transparency and a 4-star Charity Navigator rating.
Operationally, TAG functions as a coalition partner within a broader advocacy ecosystem, working alongside Black AIDS Institute, Southern AIDS Coalition, KNCV, Stop TB Partnership, AfroCAB, and NIAID clinical trial networks. Its 2026 communications director hire, the Wakefield Award, and the Southern AIDS Coalition partnership mark its current strategic emphasis on geographic expansion (U.S. South), communications capacity, and coalition-driven policy influence.
Treatment Action Group firmographics
Firmographics- Name
- Treatment Action Group
- Legal name
- Treatment Action Group
- Website
- https://treatmentactiongroup.org
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Treatment Action Group (TAG) is an independent, activist research and policy think tank founded in 1992 that fights HIV, tuberculosis, and hepatitis C through scientific research, policy advocacy, and community organizing, serving researchers, clinicians, donors, and affected communities globally.
- Ownership category
- akta.pro rank
Treatment Action Group industry classification
Industry- Product category
- Public Health Advocacy and Policy Research
- NAICS
- Other Social Advocacy Organizations (813319), Social Advocacy Organizations (8133), Voluntary Health Organizations (813212)
- SIC
- Services-Social Services (8300), Services-Health Services (8000)
- akta.pro primary industry
- Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)
Keywords
Where Treatment Action Group is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Treatment Action Group business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Individual Donations: TAG receives donations from individual supporters through direct contributions, monthly giving programs, stock gifts, and planned giving/bequests.
- Foundation Grants: TAG receives grants from foundations including Bill & Melinda Gates Foundation ($4.7 million grant in 2007 for TB/HIV research) and Unitaid for various projects including ASCENT DR-TB and LONGEVITY projects.
- Corporate Sponsorship: TAG receives corporate sponsorships for its annual Research in Action Awards (RIAA) event, including sponsors at various levels ($25,000, $10,000, $8,000, $2,500, $1,000).
- Limited Art Editions: TAG sells limited edition artworks donated by visual artists at its annual RIAA event as a fundraising mechanism.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
Treatment Action Group product offering
Product offeringCore offering
Treatment Action Group is an independent, activist, community-based research and policy think tank that produces research publications, policy reports, and advocacy resources to accelerate treatment research and maximize equitable access to prevention, diagnosis, and treatment for HIV, tuberculosis, and hepatitis C. Its primary deliverables include the annual HIV/HCV/TB Pipeline Report, TAGline newsletter, TB Research Funding Trends reports, and the Research Toward a Cure clinical trials database. TAG mobilizes affected communities, scientists, and policymakers through open collective action.
Product overview
Treatment Action Group (TAG) is an independent activist research and policy organization focused on ending HIV, tuberculosis (TB), and hepatitis C (HCV) pandemics. Rather than a technology product company, TAG offers a portfolio of research publications and advocacy resources including the annual Pipeline Report covering HIV/HCV/TB diagnostics and treatments, TAGline newsletter, TB Research Funding Trends reports, HIV cure-related clinical trials database, HIV & Aging resources, Cure-Related Research Resources, and the Long-Acting Technologies Resource Compendium. These publications and databases serve as the primary tools for community advocates, researchers, and policymakers working in global health.
Differentiator
Problem solved
Functional benefit
Products and services
- Pipeline Report Annual comprehensive review providing an overview of research and development innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). Includes detailed updates on antiretroviral therapy, HIV vaccines, PrEP, cure research, TB diagnostics, and TB treatment. Widely cited by researchers as an authoritative reference.
- TAGline Regular publication providing news on the fight to end HIV/AIDS, hepatitis C, and tuberculosis. Documents advocacy efforts, policy positions, and organizational activities for community advocates, researchers, and policymakers.
- TB Research Funding Trends Report Annual report tracking public, private, philanthropic, and multilateral institution spending on TB research and development across six areas: basic science, diagnostics, drugs, vaccines, operational research, and infrastructure. Published since 2006 as the leading reference document on TB R&D investments.
- Research Toward a Cure Trials Database Monthly-updated listing of clinical trials and observational studies related to HIV cure research, derived from clinicaltrials.gov. Includes information on trial design, enrollment criteria, principal investigators, locations, and published results. Used by advocates, researchers, and communities to track progress toward an HIV cure.
- Long-Acting Technologies Resource Compendium Non-exhaustive list of materials covering long-acting technologies for hepatitis C, latent tuberculosis infection, and malaria under the LONGEVITY Project. Includes trials tracker and illustrated glossary, advancing research and uptake of long-acting technologies for communities most in need.
Companies that use Treatment Action Group
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Treatment Action Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Treatment Action Group partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- Black AIDS Institute (BAI)coreTAG partners with Black AIDS Institute to facilitate robust community engagement in domestic HIV research. Together they developed the We The People Research Cohort, addressing lack of minority representation within research protocol development and participation.
- Southern AIDS Coalition (SAC)coreTAG partners with Southern AIDS Coalition on community engagement efforts, particularly in the Southern U.S. where HIV impact is disproportionately high. Together they support HIV advocacy training centered on Black and Brown community needs.
- Fred HutchminorTAG's partnership with Black AIDS Institute and Southern AIDS Coalition has support from Fred Hutch (Fred Hutchinson Cancer Research Center).
- KNCV Tuberculosis FoundationcoreTAG partners with KNCV Tuberculosis Foundation on the ASCENT DR-TB project, funded by Unitaid, aiming to improve access to shorter, safer, and more effective treatment regimens for drug-resistant TB and comprehensive person-centered quality care.
- Stop TB PartnershipcoreTAG has partnered with Stop TB Partnership since 2008 for international advocacy on TB/HIV research and treatment, including holding satellite meetings at Union World Conferences.
- Long-Acting Technologies Community Advisory Board (LAT CAB)coreTAG and AfroCAB formed the Long-Acting Technologies Community Advisory Board (LAT CAB) to implement meaningful, equitable solutions and research to serve communities that need them most. LAT CAB advances LAT research and uptake under the Unitaid-funded LONGEVITY project.
- African Community Advisory Board (AfroCAB)coreTAG co-founded LAT CAB with AfroCAB to advance research and uptake of long-acting technologies for communities most in need, particularly under the Unitaid-funded LONGEVITY project.
- AIDS Research Advisory Council (ARAC)minorTAG provides recommendations to ARAC on NIAID's support of HIV clinical trial networks including ACTG, IMPAACT, HPTN, and HVTN.
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG)coreACTG is one of the four Division of AIDS-sponsored HIV clinical research networks that TAG advocates for continued NIAID funding and support.
- International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT)coreIMPAACT is one of the four HIV clinical research networks that TAG supports through advocacy to ensure continued funding and comprehensive research portfolios.
- HIV Prevention Trials Network (HPTN)coreHPTN is one of the four major HIV clinical research networks that TAG advocates for, focusing on prevention trials.
- HIV Vaccine Trials Network (HVTN)coreHVTN is the largest publicly funded collaboration facilitating HIV/AIDS vaccine evaluations. TAG works to ensure continued support and funding for the network.
- COVID-19 Prevention Network (CoVPN)minorTAG developed fact sheets in partnership with CoVPN and Black AIDS Institute to foster community understanding of COVID-19 vaccine research.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Treatment Action Group competitors and assessment
Company assessmentBroad incumbents
- Partners in Health: Larger global health nonprofit delivering healthcare and fighting disease including HIV and TB in resource-poor settings. Broader incumbent operating in the same disease areas as TAG but with a service-delivery rather than research/policy focus.
- Clinton Health Access Initiative (CHAI): Global health organization working to save lives by improving access to quality healthcare for HIV/AIDS, TB, and other diseases. Comparable on treatment access advocacy and partnerships with ministries of health, with significantly larger scale and operational footprint.
- Médecins Sans Frontières / Doctors Without Borders: Massive international medical humanitarian organization that combines direct service delivery with high-profile advocacy on access to medicines. Comparable on the advocacy and policy side, particularly on TB drug pricing and access issues that intersect with TAG's mission.
Direct peers
- TB Alliance: Global nonprofit product development partnership working to develop and deliver faster, better tuberculosis treatments. Direct peer in the TB advocacy/R&D space, with overlap on the ASCENT DR-TB project KNCV partnership ecosystem and shared Unitaid funding streams.
- AIDS United: U.S.-based national organization that advocates for people living with and affected by HIV. Direct peer in domestic HIV policy advocacy, with overlapping focus on Southern U.S. jurisdictions, Black and Brown communities, and Ending the Epidemic initiatives.
- Health GAP (Global Access Project): Activist organization fighting for equitable global access to HIV treatment and medicines. Direct peer sharing TAG's policy/advocacy focus and ACT UP lineage, with comparable size and mission around treatment access and drug pricing activism.
- amfAR (Foundation for AIDS Research): One of the world's leading HIV/AIDS research and advocacy nonprofits. Directly comparable to TAG as a disease-focused advocacy and research funder, though amfAR is significantly larger and emphasizes direct research funding while TAG focuses on policy and access advocacy.
- International Treatment Preparedness Coalition (ITPC): Global coalition of people living with HIV and community activists focused on access to optimal HIV treatment. Direct peer in treatment-access advocacy with similar lean operating model and community-led approach, especially in middle-income countries.
- DNDi (Drugs for Neglected Diseases initiative): International not-for-profit R&D organization developing treatments for neglected diseases including HCV and TB. Comparable model of advocating for and accelerating R&D for diseases disproportionately affecting low-income populations, with overlapping funder relationships.
- AVAC (AIDS Vaccine Advocacy Coalition): Global HIV prevention research advocacy organization focused on accelerating the development and delivery of HIV prevention tools (vaccines, PrEP). Direct peer with overlapping HIV cure/vaccine research advocacy and similar publication-driven model (think tank/research outputs).
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Treatment Action Group social profiles
Digital presenceTreatment Action Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Treatment Action Group leadership team
Management profileNumber of profiles
Profiles15 records
Treatment Action Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Treatment Action Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Treatment Action Group
What does Treatment Action Group do?
Treatment Action Group is an independent, activist, community-based research and policy think tank that produces research publications, policy reports, and advocacy resources to accelerate treatment research and maximize equitable access to prevention, diagnosis, and treatment for HIV, tuberculosis, and hepatitis C. Its primary deliverables include the annual HIV/HCV/TB Pipeline Report, TAGline newsletter, TB Research Funding Trends reports, and the Research Toward a Cure clinical trials database. TAG mobilizes affected communities, scientists, and policymakers through open collective action.
Is Treatment Action Group a public or private company?
Treatment Action Group is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Treatment Action Group founded?
Treatment Action Group was founded in 1992. It employs 1 to 10 people.
Where is Treatment Action Group based?
Treatment Action Group is headquartered in New York, United States, in the North America region.
How does Treatment Action Group make money?
Four revenue lines are on record. Individual Donations are the primary driver. The others are foundation Grants, corporate Sponsorship and limited Art Editions.
Who are Treatment Action Group's main competitors?
Broad incumbents on record are Partners in Health, Clinton Health Access Initiative (CHAI) and Médecins Sans Frontières / Doctors Without Borders. Direct peers are TB Alliance, AIDS United, Health GAP (Global Access Project), amfAR (Foundation for AIDS Research), International Treatment Preparedness Coalition (ITPC), DNDi (Drugs for Neglected Diseases initiative) and AVAC (AIDS Vaccine Advocacy Coalition).
Does Treatment Action Group have an API?
No public API is recorded for Treatment Action Group.
What industry is Treatment Action Group in?
Treatment Action Group's product category is Public Health Advocacy and Policy Research. Its primary akta.pro industry code is HLAJAKAN, Global Health Research, Evidence & Technical Assistance Organizations. Its NAICS code is 813319 and its SIC code is 8300.